E Woodward1, M Jessop2, A Glaser3, D Stark4. 1. Cancer Medicine, St James's Institute of Oncology, Leeds Teaching Hospitals NHS Trust, Leeds; Section of Oncology and Clinical Research, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK. 2. Cancer Medicine, St James's Institute of Oncology, Leeds Teaching Hospitals NHS Trust, Leeds; Department of Paediatric Oncology, Queensland Children's Cancer Centre, Brisbane, Australia. 3. Department of Paediatric Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, UK. 4. Cancer Medicine, St James's Institute of Oncology, Leeds Teaching Hospitals NHS Trust, Leeds; Section of Oncology and Clinical Research, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK. Electronic address: d.p.stark@leeds.ac.uk.
Abstract
BACKGROUND: Late effects (LEs) after cancer treatment are increasing. After childhood cancer, substantial risks include physical, psychological and social LE and vary with age. Teenagers and young adults (TYA) present with particular cancers; their risk of LE may relate to cancer site, treatment or their age itself. The LEs after TYA-onset cancers are described in relation to age at diagnosis of primary tumour. PATIENTS AND METHODS: Data were extracted from Medline English language articles, 1999-2009. Keywords were late effect/s, late toxicity and survivor and the frequent TYA cancer sites. Only those articles that reported the relation between LEs risks with age at diagnosis were included. RESULTS: The majority of known LEs are described after TYA cancer. No study primarily aimed to relate TYA age to LEs. Many studies did not report LE by age. TYA-specific risks are seen in cardiac toxicity, second malignancies, pulmonary complications and psychosocial difficulties when compared with older or younger cancer survivors. CONCLUSIONS: TYA age brings specific LE risks after cancer. Prospective population-based collection of LE data after TYA cancer will inform the development of appropriate services to effectively manage LE.
BACKGROUND: Late effects (LEs) after cancer treatment are increasing. After childhood cancer, substantial risks include physical, psychological and social LE and vary with age. Teenagers and young adults (TYA) present with particular cancers; their risk of LE may relate to cancer site, treatment or their age itself. The LEs after TYA-onset cancers are described in relation to age at diagnosis of primary tumour. PATIENTS AND METHODS: Data were extracted from Medline English language articles, 1999-2009. Keywords were late effect/s, late toxicity and survivor and the frequent TYAcancer sites. Only those articles that reported the relation between LEs risks with age at diagnosis were included. RESULTS: The majority of known LEs are described after TYAcancer. No study primarily aimed to relate TYA age to LEs. Many studies did not report LE by age. TYA-specific risks are seen in cardiac toxicity, second malignancies, pulmonary complications and psychosocial difficulties when compared with older or younger cancer survivors. CONCLUSIONS:TYA age brings specific LE risks after cancer. Prospective population-based collection of LE data after TYAcancer will inform the development of appropriate services to effectively manage LE.
Authors: Richard Baird; Ian Banks; David Cameron; John Chester; Helena Earl; Mark Flannagan; Adam Januszewski; Richard Kennedy; Sarah Payne; Emlyn Samuel; Hannah Taylor; Roshan Agarwal; Samreen Ahmed; Caroline Archer; Ruth Board; Judith Carser; Ellen Copson; David Cunningham; Rob Coleman; Adam Dangoor; Graham Dark; Diana Eccles; Chris Gallagher; Adam Glaser; Richard Griffiths; Geoff Hall; Marcia Hall; Danielle Harari; Michael Hawkins; Mark Hill; Peter Johnson; Alison Jones; Tania Kalsi; Eleni Karapanagiotou; Zoe Kemp; Janine Mansi; Ernie Marshall; Alex Mitchell; Maung Moe; Caroline Michie; Richard Neal; Tom Newsom-Davis; Alison Norton; Richard Osborne; Gargi Patel; John Radford; Alistair Ring; Emily Shaw; Rod Skinner; Dan Stark; Sam Turnbull; Galina Velikova; Jeff White; Alison Young; Johnathan Joffe; Peter Selby Journal: Ecancermedicalscience Date: 2016-01-05
Authors: Kyle Strodtbeck; Andrew Sloan; Lisa Rogers; Paul Graham Fisher; Duncan Stearns; Laura Campbell; Jill Barnholtz-Sloan Journal: J Neurooncol Date: 2013-02-08 Impact factor: 4.130
Authors: Sara J Stoneham; Juliet P Hale; Carlos Rodriguez-Galindo; Ha Dang; Thomas Olson; Matthew Murray; James F Amatruda; Claire Thornton; G Suren Arul; Deborah Billmire; Mark Krailo; Dan Stark; Al Covens; Jean Hurteau; Sally Stenning; James C Nicholson; David Gershenson; A Lindsay Frazier Journal: Oncologist Date: 2014-06-04